Travere Therapeutics
TVTX
116 hedge funds and large institutions have $691M invested in Travere Therapeutics in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 36 closing their positions.
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
52% more call options, than puts
Call options by funds: $61.1M | Put options by funds: $40.2M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
4% less capital invested
Capital invested by funds: $719M → $691M (-$27.2M)
13% less funds holding
Funds holding: 133 → 116 (-17)
47% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.9M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$7.39M |
| 3 |
SCM
Scopia Capital Management
New York
|
+$7.37M |
| 4 |
BC
Broadfin Capital
New York
|
+$6.99M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$6.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$10.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$6.28M |
| 3 |
QF
QVT Financial
New York
|
-$6.01M |
| 4 |
Morgan Stanley
New York
|
-$4.92M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.88M |
TVTX Hedge Fund Activity: Q4 2015 in Review
116 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2015, worth a combined $691M — down 3.8% from $719M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of TVTX and 19 opened new positions — a net loss of 17 holders — while 31 trimmed existing stakes and 51 added.
The largest buyer was Fidelity Investments, adding an estimated $12.9M. The largest seller was Putnam Investments, exiting entirely with an estimated $10.8M sold.
- 116 institutional investors held Travere Therapeutics (TVTX) as of Q4 2015, down from 133 in Q3 2015.
- Funds reported $691M of Travere Therapeutics stock for Q4 2015, down 3.8% quarter-over-quarter.
- 19 funds opened new Travere Therapeutics positions in Q4 2015 and 36 closed out, a net change of -17 holders.
- The largest Travere Therapeutics buyer in Q4 2015 was Fidelity Investments, an estimated $12.9M added.
- The largest Travere Therapeutics seller in Q4 2015 was Putnam Investments, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2015.